

Supplementary Table 1: List of cell line models used for drug screening.

Cell line	Entity	p53 status	MYC status	Reference
CHLA-01-MED	MB	wt (1)	MYC amplification (1)	(1)
CHLA-01R-MED	MB	wt (1)	MYC amplification (1)	(1)
D283 MED	MB	wt (2)	No MYC amplification (3), high-level gain (4)	(5)
D341 MED	MB	wt (2, 6)	MYC amplification (7)	(7)
D425 MED	MB	m(8)	MYC amplification (3), MYCN amplification (8)	(3)
MED8A	MB	wt (8)	PVT1-MYC fusion (9), MYC amplification (10)	(11)
MB3W1	MB	-	MYC amplification (12)	(12)
MB002	MB	-	MYC amplification (13)	(13)
HD-MB03	MB	wt (14)	MYC amplification (14)	(14)
CHLA-259	MB	wt (15)	High MYCN expression (16)	(15)
Daoy	MB	m (8)	High MYCN expression (15)	(17)
ONS76	MB	wt (8)	-	(18)
UW-228-2	MB	m (6, 8)	-	(19)
UW-228-3	MB	m (6, 8)	-	(19)
ATRT13808	AT/RT	-	-	unpublished
BT-12	AT/RT	-	-	(20)
BT-16	AT/RT	-	-	(20)
CHLA-02-ATRT	AT/RT	-	-	(21)
CHLA-04-ATRT	AT/RT	-	-	(21)
CHLA-05-ATRT	AT/RT	-	-	(16)
CHLA-06-ATRT	AT/RT	-	-	(16)
CHLA-266	AT/RT	-	-	(15)
HHU-ATRT-01	AT/RT	-	-	unpublished
JC-ATRT	AT/RT	-	-	unpublished
VU397	AT/RT	-	-	unpublished
AM-38	GBM	-	-	(22)
LN-18	GBM	-	-	(23)
LN-308	GBM	-	-	(24)
LN-229	GBM	-	-	(23)
SJ-GBM2	GBM	-	-	(25)
T98G	GBM	-	-	(26)
TP365MG	GBM	-	-	(27)
U138MG	GBM	-	-	(28)
U251MG	GBM	-	-	(29)
U87MG	GBM	-	-	(29)
YH-13	GBM	-	-	(22)

Supplementary references

- 1 Xu J, Margol AS, Shukla A, Ren X, Finlay JL, Krieger MD, et al. Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. *Frontiers in Oncology* 2015; 5: 191.
- 2 Saylors RL, III, Brodeur GM, Bigner DD. Infrequent p53 Gene Mutations in Medulloblastomas. *Cancer Research* 1991; 51: 4721-23.
- 3 Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the *c-myc* Gene in Human Medulloblastoma Cell Lines and Xenografts. *Cancer Research* 1990; 50: 2347-50.
- 4 Siu IM, Lal A, Blankenship JR, Aldosari N, Riggins GJ. *c-Myc* Promoter Activation in Medulloblastoma. *Cancer Research* 2003; 63: 4773.
- 5 Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Wikstrand CJ, Halperin EC, et al. Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med. *Journal of Neuropathology & Experimental Neurology* 1985; 44: 592-605.
- 6 Schramm A, Eggert A, Speleman F, Deubzer HE, Schulte JH, De Preter K, et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. *Neuro-Oncology* 2012; 14: 859-69.
- 7 Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Brodeur GM, He X, et al. Phenotypic and Genotypic Analysis of a Human Medulloblastoma Cell Line and Transplantable Xenograft (D341 Med) Demonstrating Amplification of *c-myc*. *The American Journal of Pathology* 1988; 130: 472-84.
- 8 Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S, et al. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. *International Journal of Cancer* 2014; 134: 703-16.
- 9 Northcott PA, Shih DJH, Peacock J, Garzia L, Sorana Morrissy A, Zichner T, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature* 2012; 488: 49-56.
- 10 Langdon JA, Lamont JM, Scott DK, Dyer S, Prebble E, Bown N, et al. Combined genome-wide allelotyping and copy number analysis identify frequent genetic losses without copy number reduction in medulloblastoma. *Genes Chromosomes Cancer* 2006; 45: 47-60.
- 11 Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson ADJ, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. *Carcinogenesis* 2004; 25: 661-68.
- 12 Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, et al. MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. *BMC Cancer* 2016; 16: 115.
- 13 Bandopadhyay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, et al. BET Bromodomain Inhibition of *MYC*-Amplified Medulloblastoma. *Clinical Cancer Research* 2014; 20: 912-25.
- 14 Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, et al. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. *J Neurooncol* 2012; 110: 335-48.
- 15 Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, et al. Novel cell lines established from pediatric brain tumors. *Journal of Neuro-Oncology* 2012; 107: 269-80.
- 16 Erdreich-Epstein A, Robison N, Ren X, Zhou H, Xu J, Davidson TB, et al. *PID1* (*NYGGF4*), a new growth-inhibitory gene in embryonal brain tumors and gliomas. *Clinical cancer research* 2014; 20: 827-36.
- 17 Jacobsen PF, Jenkyn DJ, Papadimitriou JM. Establishment of a Human Medulloblastoma Cell Line and Its Heterotransplantation into Nude Mice. *Journal of Neuropathology & Experimental Neurology* 1985; 44: 472-85.
- 18 Yamada M, Shimizu K, Tamura K, Okamoto Y, Matsui Y, Moriuchi S, et al. Establishment and biological characterization of human medulloblastoma cell lines. *No to shinkei* 1989; 41: 695-702.
- 19 Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR. Establishment and characterization of four human medulloblastoma-derived cell lines. *Oncol Res* 1995; 7: 493-503.
- 20 D'cunja J, Shalaby T, Rivera P, von Büren A, Patti R, Heppner FL, et al. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. *European Journal of Cancer* 2007; 43: 1581-89.
- 21 Xu J, Margol A, Asgharazadeh S, Erdreich-Epstein A. Pediatric brain tumor cell lines. *J Cell Biochem* 2015; 116: 218-24.
- 22 Izumu I, Mineura K, Watanabe K, Kowada M. Characterization and chemosensitivity of two cell lines derived from human glioblastomas. *Journal of Neuro-Oncology* 1993; 17: 111-21.

- 23 Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF, Carrel S. Characterization of an established human malignant glioma cell line: LN-18. *Acta Neuropathol* 1981; 53: 21-8.
- 24 Studer A, de Tribolet N, Diserens AC, Gaide AC, Matthieu JM, Carrel S, et al. Characterization of four human malignant glioma cell lines. *Acta Neuropathol* 1985; 66: 208-17.
- 25 Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. *Cancer Chemotherapy and Pharmacology* 1995; 36: 393-403.
- 26 Stein GH. T98G: An anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. *Journal of Cellular Physiology* 1979; 99.
- 27 Collins VP. Cultured human glial and glioma cells. *Int Rev Exp Pathol* 1983; 24: 135-202.
- 28 Beckman G, Beckman L, Pontén J, Westermark B. G-6-PD and PGM phenotypes of 16 continuous human tumor cell lines. Evidence against cross-contamination and contamination by HeLa cells. *Hum Hered* 1971; 21: 238-41.
- 29 Pontén J, Macintyre EH. Long term culture of normal and neoplastic human glia. *Acta Pathologica Microbiologica Scandinavica* 1968; 74: 465-86.